Literature DB >> 27839541

Missing Information.

Armin Mainz1.   

Abstract

Year:  2016        PMID： 27839541      PMCID： PMC5143800          DOI： 10.3238/arztebl.2016.0692a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Authors:  Fernando J Martinez; Peter M A Calverley; Udo-Michael Goehring; Manja Brose; Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet       Date:  2015-02-13       Impact factor: 79.321

2.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Authors:  Leonardo M Fabbri; Peter M A Calverley; José Luis Izquierdo-Alonso; Daniela S Bundschuh; Manja Brose; Fernando J Martinez; Klaus F Rabe
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

3.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Authors:  Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

Review 4.  The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Adrian Gillissen; Peter Haidl; Martin Khlhäufl; Klaus Kroegel; Thomas Voshaar; Christian Gessner
Journal:  Dtsch Arztebl Int       Date:  2016-05-06       Impact factor: 5.594
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.